In a significant advancement for cancer research, China's Center for Drug Evaluation of the National Medical Products Administration has approved Phase-I clinical trials for an innovative mRNA vaccine targeting Epstein-Barr virus (EBV) positive tumors.
The groundbreaking vaccine, developed independently by WestGene Biopharma based in Chengdu, Sichuan Province, marks a pivotal moment in tumor immunotherapy. Earlier this year, the vaccine secured Investigational New Drug approval from the U.S. Food and Drug Administration, paving the way for its current clinical trial phase.
Epstein-Barr virus, identified as a Group-I carcinogen by the International Agency for Research on Cancer, is associated with over ten types of malignant tumors, including nasopharyngeal carcinoma, lymphoma, and gastric cancer. Song Xiangrong, co-founder of WestGene Biopharma, highlighted the virus as the first human oncogenic virus discovered, underscoring the vaccine's potential impact.
The development of this mRNA tumor therapeutic vaccine represents a major breakthrough in the realm of mRNA-based innovative drugs. By harnessing the power of mRNA technology, the vaccine aims to bolster the body's immune response against EBV-related cancers.
WestGene Biopharma is poised to conduct clinical trials nationwide, accelerating the application of this promising mRNA vaccine to combat EBV-positive tumors and improve patient outcomes.
Reference(s):
cgtn.com
